SC
PCVX icon

Samlyn Capital’s Vaxcyte PCVX Stock Holding History

Samlyn Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-302,679
Closed -$20.7M – 108
2024
Q1 		$20.7M Sell
302,679
-26,530
-8% -$1.84M 0.35% 75
2023
Q4 		$20.7M Buy
+329,209
New +$17.1M 0.41% 60

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Samlyn Capital's PCVX Position: Q2 2024 in Review

Samlyn Capital sold out of Vaxcyte (PCVX) in Q2 2024, closing a stake of 302,679 shares — an estimated $20.7M sold.

Samlyn Capital first reported a position in PCVX in Q4 2023 and held it in 2 quarters. The position peaked at $20.7M in Q1 2024. 265 funds tracked by Wall St. Rank hold PCVX as of Q2 2024.

  • Samlyn Capital reported no remaining Vaxcyte position as of Q2 2024 after selling out during the quarter.
  • Samlyn Capital sold 302,679 Vaxcyte shares in Q2 2024, an estimated $20.7M.
  • Samlyn Capital first reported a position in Vaxcyte in Q4 2023 and held it in 2 quarters.
  • Samlyn Capital's Vaxcyte position peaked at $20.7M in Q1 2024.
  • 265 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2024.

Based on Samlyn Capital's 13F filing for Q2 2024, filed 14 Aug 2024.